Best NAD+ Supplements, Rated by Evidence (2026)

If you have shopped for an “NAD+ supplement,” you have met a confusing shelf: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), plain niacin, nicotinamide, “liposomal NAD+,” sublingual lozenges, and IV drips — all promising the same thing, more energy and slower aging, at wildly different prices. This roundup rates those classes the only way that is honest: by what human trials actually show.

The single most important fact to carry through every section is this. Oral NAD+ precursors do reliably raise the NAD+ biomarker in human blood — but raising that biomarker has not been shown to deliver the energy, anti-aging, or longevity outcomes the marketing implies. “It raised my NAD+” and “it made me younger” are two very different claims, and almost the entire body of evidence supports only the first. These are supplements, not approved drugs; none is FDA-approved to treat, prevent, or cure anything, and most products are not third-party tested for purity or dose accuracy. We unpack the underlying science in our pillar guide, NAD+ therapy: what the evidence actually shows.

How we rated the classes

We grouped products by their active ingredient — not by brand — and graded each on what controlled human data exist:

• •🟢 Strongest evidence — multiple randomized human trials confirm the basic effect (it raises NAD+ and is well tolerated), even if downstream outcome benefits remain unproven.
• •🟡 Mixed / emerging — some human trials exist, but they are small, short, surrogate-marker-based, or conflicting.
• •🔴 Weak / mechanism-only — claims rest on lab, animal, or marketing rationale rather than controlled human outcome data, or the route itself is unproven.

A 🟢 grade is not an endorsement that the supplement will make you feel better. It means the most basic claim — “this raises NAD+ in people and appears safe short-term” — is backed by randomized data. That is a low bar, and it is roughly where the entire category sits.

🟢 Nicotinamide riboside (NR) — the best-studied precursor

NR (sold most prominently as Niagen, and in consumer products like Tru Niagen and Basis) has the deepest controlled-trial record of any NAD+ precursor. The foundational human work showed NR is orally bioavailable and raises blood NAD+ in a dose-dependent way¹. A randomized crossover trial in healthy middle-aged and older adults then confirmed that chronic NR is well tolerated and durably elevates NAD+², and a longer randomized safety study of Niagen specifically (nicotinamide riboside chloride) found long-term administration safe at studied doses³. For a brand-level deep dive into the most-studied NR product, see our Tru Niagen review.

Where NR stays honest is on outcomes. The trials reliably show the biomarker moving; they have not reliably shown the things people buy it for. A randomized phase I trial in Parkinson's disease (NADPARK) showed NR raised brain NAD levels and hinted at mild clinical signals, but was explicitly an early-stage, biomarker-focused study — not proof of benefit⁵. Another trial found oral NR lowered some blood biomarkers of neurodegenerative pathology, an intriguing mechanistic finding that is a long way from “prevents dementia”⁴. So NR earns 🟢 for the narrow, well-supported claim — raises NAD+, well tolerated — and nothing more. (The human trials cluster around 250–1,000 mg/day; for the full breakdown of studied doses by form, see our NAD+ dosage guide.)

🟡 Nicotinamide mononucleotide (NMN) — popular, real human data, big regulatory cloud

NMN is the precursor with the most hype (it is the molecule behind much of the “Sinclair stack” attention) and a genuine — if thinner — human-trial base. The first human safety/pharmacokinetic study showed a single oral dose was safely metabolized⁶, and a dose-ranging randomized trial in healthy middle-aged adults reported NMN raised blood NAD+ and was well tolerated across doses⁸. A long-term follow-up study reported safety over extended supplementation with some sleep and metabolic readouts⁷.

The downstream-outcome data are where NMN gets interesting but stays unproven. A well-publicized randomized trial in prediabetic women found NMN improved muscle insulin sensitivity⁹ — a real, peer-reviewed result, but in a specific population and not a general fitness or anti-aging claim. Small trials have reported improved aerobic capacity in amateur runners¹⁰ and better self-reported sleep, fatigue, and physical performance in older adults¹¹. These are encouraging signals, not settled conclusions: the studies are small, short, often industry-linked, and built on soft endpoints.

NMN also carries a regulatory cloud that NR does not. U.S. regulators reversed course on whether NMN can be sold as a dietary supplement at all, after it was investigated as a drug — a saga that has repeatedly disrupted availability and made third-party purity testing especially important here. We document that in full in why people stop taking NMN (and the FDA NMN saga), and we compare the two leading precursors head-to-head in NMN vs NR: what the human trials show. If you've already decided on NMN, our dedicated guide to choosing an NMN supplement by evidence and purity covers third-party testing and the β-NMN form. NMN lands at 🟡: real human data, but smaller and shakier than NR, plus a regulatory question mark.

🟡 Niacin (nicotinic acid) — cheap, proven to fix deficiency, not an “NAD+ optimizer”

Niacin (vitamin B3, nicotinic acid) is the original NAD+ precursor and costs pennies. It is genuinely effective for one thing the trendy products are not even claiming: correcting B3 deficiency. Severe deficiency causes pellagra — the classic dermatitis, diarrhea, and dementia — which niacin reliably treats and prevents¹³. That is real, well-established medicine.

But niacin is a poor fit for “NAD+ optimization” in already-replete people. It raises NAD precursors but is infamous for flushing — an intense, harmless-but-unpleasant skin reaction — at the doses that move the needle, and high-dose niacin has its own cardiovascular and liver-safety considerations that put it outside casual self-supplementation. So it earns 🟡: strong evidence for a different job (deficiency), weak evidence for the wellness claims that NR/NMN marketing borrows.

🟡 Nicotinamide (niacinamide) — strongest *outcome* trial in the family is about skin, not energy

Nicotinamide (niacinamide), another B3 form, is the one NAD-family ingredient with a large, rigorous, randomized outcome trial — and tellingly, that outcome is dermatologic. In the phase 3 ONTRAC trial, oral nicotinamide 500 mg twice daily reduced new non-melanoma skin cancers in high-risk patients versus placebo¹². That is the most robust hard-endpoint result in this entire roundup. It does not, however, support energy, longevity, or anti-aging claims, and the benefit did not persist after stopping. Nicotinamide is cheap and well tolerated (it does not cause niacin's flush), but as an “NAD+ supplement” for vitality it sits at 🟡 — proven for a narrow skin indication, unproven for the rest.

🔴 “Liposomal NAD+” and sublingual NAD+ — the route is the problem

Products that sell NAD+ itself — liposomal capsules, sublingual lozenges, “stabilized NAD+” sprays — rest on a claim the human pharmacokinetic literature does not support: that intact NAD+ survives and is absorbed better than the cheap precursors. The controlled human absorption data that exist are for the precursors (NR, NMN), not for swallowed or dissolved NAD+ molecules, and there is no good human trial showing a liposomal or sublingual NAD+ product raises blood NAD+ better than NR does. We go deeper in liposomal NAD+: does the delivery claim hold up?. Until a product publishes human absorption data, “liposomal NAD+” is 🔴 — a delivery story without the trial to back it.

🔴 IV NAD+ — highest cost, lowest evidence

IV NAD+ drips are the most expensive option by far and the least supported by controlled outcome data. Infusing NAD+ does bypass the gut, but there are no randomized trials showing IV NAD+ improves energy, cognition, addiction recovery, or aging outcomes; the marketed uses run well ahead of the evidence, and infusion carries its own discomforts and risks. We lay out what is and isn't known — and the real-world price bands — in NAD+ IV therapy: evidence and cost and the related NAD+ injections: what the research shows. IV is 🔴: cost is not a proxy for efficacy.

Buying honestly: purity and third-party testing matter more than the route

Because these are supplements, not drugs, what is on the label is not guaranteed to be in the bottle. Independent analyses have repeatedly found NMN and NAD products that under-deliver — or contain little active ingredient at all. Practical, honest guidance:

• •Prefer NR or NMN with third-party testing (a Certificate of Analysis, or NSF/USP-type verification) over exotic “liposomal NAD+” or IV unless a clinician advises otherwise. NR (Niagen) has both the deepest trials and the cleanest regulatory status.
• •Don't pay for the route — there is no human evidence that liposomal or IV NAD+ beats a well-made NR or NMN capsule at raising the biomarker.
• •Expect a biomarker change, not a transformation. Realistically, what these reliably do is raise NAD+; whether you feel anything is unproven. We collected the honest version of that in NAD+ before and after: what to realistically expect, and the safety picture by route in NAD+ side effects.
• •Talk to a clinician if you take niacin at high dose, have liver issues, are pregnant, or have a cancer history — NAD+ biology and cancer is genuinely two-sided, which we cover in NAD+ and cancer.

For our full editorial ranking of the brands and clinics selling these — featured partner plus vetted independents, with honest red flags — see our best NAD+ providers hub. That ranking is editorial and evidence-driven: we never let a commercial relationship move the order.

The bottom line

Rated by evidence, the NAD+ supplement shelf collapses to a simple picture. NR (🟢) is the best-studied: it reliably raises NAD+ and is well tolerated, with outcomes still unproven. NMN (🟡) has real but smaller human data plus a regulatory cloud. Niacin and nicotinamide (🟡) are proven for narrow, non-vitality jobs — deficiency and (for nicotinamide) skin-cancer prevention — not for the energy and anti-aging claims that get borrowed for them. Liposomal NAD+ and IV (🔴) charge the most for the least evidence. Across the board, the precursors move the biomarker; the human outcomes people are buying remain largely unproven. Buy on purity and trial depth, not on the drama of the delivery — and keep your expectations honest.